STOCK RESCISSION AGREEMENTStock Rescission Agreement • February 12th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances)
This STOCK RESCISSION AGREEMENT (this “Agreement”) is made and entered into as of February 10, 2024 (the “Effective Date”), by and between CHROMOCELL THERAPEUTICS CORPORATION (the “Company”) and certain affiliates of A.G.P./Alliance Global Partners who hold shares of common stock, par value $0.0001 (the “Common Stock”) of the Company identified on the signature page hereto (each, an “A.G.P. Affiliate” and collectively, the “A.G.P. Affiliates”).
FIRST AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTESecurities Purchase Agreement • February 12th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances)
This First Amendment to Senior Secured Convertible Note (this “Amendment”) dated as of February 8, 2024 (the “Effective Date”) is entered into by and between Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”), and Zach Hirsch (the “Purchaser”).
FOURTH AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTEConvertible Note • February 12th, 2024 • Chromocell Therapeutics Corp • Biological products, (no disgnostic substances)
This Fourth Amendment to Senior Secured Convertible Note (this “Amendment”) dated as of February 8, 2024 (the “Effective Date”) is entered into by and between Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”), and DB Investor Group LLC (the “Purchaser”).
